Abstract: A hand held spray device is disclosed. The spray device has a body with a reservoir, an actuator having an actuator exit orifice, a valve in fluid communication with the actuator exit orifice and the reservoir, and a propellant and antiperspirant composition stored in the reservoir. The propellant has a concentration from 30% to 70% by weight of the total fill of materials stored within the reservoir. The antiperspirant composition includes a non-volatile silicone fluid having a concentration from about 30% to about 70% by weight of the antiperspirant composition, an antiperspirant active, an organoclay material and at least one liquid activation enhancer.

Abstract: A hand held spray device is disclosed. The spray device includes a body with a reservoir, an actuator with an actuator exit orifice, a valve in fluid communication with the actuator exit orifice and the reservoir and a propellant and antiperspirant composition stored in the reservoir. The propellant has a concentration from about 30% to about 70% by weight of the total fill of materials stored within the reservoir and a boiling point at 1 atmosphere from about ?10° C. to about 10° C. The antiperspirant composition includes a liquid carrier and an antiperspirant active.

Abstract: A hand held spray device is disclosed. The spray device has a body with a reservoir to house a total fill of material, an actuator having an actuator exit orifice, a valve in fluid communication with the actuator exit orifice and the reservoir, and a propellant and antiperspirant composition stored in the reservoir. The propellant has a concentration from 72% to 90% by weight of the total fill of materials stored within the reservoir. The antiperspirant composition includes a non-volatile silicone fluid having a concentration from about 30% to about 70% by weight of the antiperspirant composition, an antiperspirant active, greater than 1% substantially inert particulates, an organoclay material, at least one liquid activation enhancer, and optionally a liquid fragrance material.

Abstract: The present invention relates to an aerosol hairspray product. The product comprises: a pressurisable container comprising a container wall which encloses a reservoir for storing a hairstyling formulation and a liquefied gas propellant; and a spraying device attached to the container for dispensing the hairstyling formulation from the reservoir of the container. The spraying device comprises a valve and a nozzle and the valve comprises a valve body, a stem and a spring means. The valve body houses an insert and the insert comprises an insert orifice and at least two channels. The channels are tangentially disposed about the insert orifice. Also the valve body comprises at least two vapour taps. Furthermore the insert orifice is capable of being in liquid communication with the hairstyling formulation in the reservoir.

Abstract: Cosmetic compositions are provided that include an extract from a seed of the Nicotiana species, one or more cosmetically acceptable carriers to act as a diluent, dispersant or carrier for the composition, and optionally one or more cosmetic adjuvants. The tobacco seed extract is typically characterized as having a significant lipid content and, thus, finds use as an oil component in a cosmetic composition.

Abstract: The present invention provides a safe and effective insecticide composition suitable for treating a subject infested with a parasitic anthropode or to prevent infestation by an arthropod. The insecticide composition is a foamable composition, including a first insecticide; at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 5%, or about 5% to about 10%; or about 10% to about 20%; or about 20% to about 50% by weight; about 0.1% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; and (5) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: A waterless foamable pharmaceutical composition suitable for external administration is disclosed. The composition includes a foamable carrier least one liquefied or compressed gas propellant. The foamable carrier includes at least one liquid oil; at least one silicone and at least one least one stabilizing agent; wherein the stabilizing agent selected from the group consisting of about 0.01% to about 25% by weight of at least one surface-active agent alone or on combination with a foam adjuvant; and about 0% to about 5% by weight of at least one polymeric agent alone or on combination with a foam adjuvant; and mixtures thereof. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.

Abstract: A sprayable alcohol-based sunscreen comprises an alcohol carrier, at least one sunscreen additive, and a film forming polymer comprising shellac.

Abstract: Compositions for personal hygiene or body care, in particular deodorants, antiperspirants, massage fluids, foot care agents, shaving aids, or oral care agents, which preferably are present as a spray, including 0-7 wt % of free water, at least one cosmetic oil that is liquid under normal conditions, an oily extract from the leaves of Rumex acetosa, and in addition to the aforementioned components at least one cooling agent, wherein the amount specifications are relative to the weight of the composition without taking into account any present propellant.

Abstract: A dietary supplement formulation for reducing the risk of coronary heart disease or stroke, and in which there is provided a plurality of vitamins and minerals that together represent a minimum daily requirement thereof. Added to this composition is aspirin and plant sterols.

Abstract: Systems and methods for neutralizing a solution comprising a compound of interest, comprising: aerosolizing a solution, wherein the solution is a low pH solution and comprises the compound of interest; contacting the aerosolized solution with ammonia vapor, wherein the ammonia vapor neutralizes at least a portion of said aerosolized solution; and removing at least some water from the neutralized aerosolized solution, wherein the neutralized aerosolized solution is at least partially dehydrated.

Abstract: Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.

Abstract: Mineral, cosmetic, pharmaceutical, agricultural, nutraceutical, and other compositions are produced using a mineral composition containing minimal concentrations of cadmium, lead, arsenic, and mercury and containing relatively high concentrations of micro and macro mineral elements, of rare earth elements, of calcium, and of silica. The mineral concentrations are produced by processing naturally occurring clay soil to concentrate mineral elements naturally occurring in the soil.

Abstract: Certain surfactants suitable for use alone to dissolve a water-insoluble component in compositions is described for providing VOC-free compressed gas aerosol compositions. The compositions include water-insoluble component(s), a surfactant and water. The water-insoluble component(s) can be active agent(s), such as fragrance(s) and/or an insecticide(s). The surfactant is present as a single surfactant which, in the absence of a solvent, dissolves or disperses the water-insoluble component(s) and provides a homogenous blend in water which provides a stable compressed gas emulsion.

Abstract: A composition for in situ formation and/or expansion of a polymer-based hemostatic agent to control bleeding includes a suitable amount of a polymer or polymer-forming component, hydrogen peroxide or chemical(s) capable of forming hydrogen peroxide, or a combination of both, and a decomposing agent for hydrogen peroxide. The decomposing agent includes an endogenously or exogenously supplied catalyst (other than catalase), or both, and/or the polymer or polymer-forming component.

Abstract: A pharmaceutical aerosol is disclosed which is suitable for delivering an active compound to the mucosa of the nose, the osteomeatal complex or a paranasal sinus. The pressure of the aerosol is not constant, but pulsates at a frequency from about 10 to 90 Hz. The aerosol is further characterized in that it exhibits a low effective flow rate of less than about 5 liters per minute. The aerosol is, inter alia, suitable for the prevention, management, or treatment of a disease, symptom, or condition affecting the nose or the paranasal sinuses, such as acute and chronic sinusitis.

Abstract: An aerosol shave composition, preferably a post foaming shave gel, comprising a hydrophobic agent, such as a silicone, in the form of a microdroplet having a particle size from about 0.15 microns to about 10 microns.

Abstract: There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.

Abstract: Methods of manufacturing effervescent dosage forms. Methods of manufacturing an effervescent tablet using a dry, direct compression process are disclosed. The methods do not result in the sticking of the mixture to be tableted to the punches during production.

Abstract: A drug and device combination system used in a method for treatment of patients suffering from severe and oral corticosteroid-dependent asthma and other respiratory diseases requiring a treatment with orally administered steroids. The method for administration of the inhalable corticosteroid by a flow rate and volume regulated inhalation. The combination system of the inhalable corticosteroid and the device for regulating flow rate and volume of the inhalable corticosteroid and thus achieving delivery of said inhalable corticosteroid into the small airways of the lungs. The individually programmable device that assures safe and reproducible corticosteroid delivery compliant with treatment protocol.

Abstract: A composition for in situ formation of an artificial blockage to control bleeding includes a suitable amount of a polymer-forming component, a suitable amount of a crosslinking agent, hydrogen peroxide, and a decomposing agent for hydrogen peroxide. The decomposing agent includes exogenous or endogenous catalase, or both.

Abstract: The present invention relates to stable substantially non-aqueous, non-alcoholic, non-silicone, foamable carrier compositions comprising petrolatum or mixtures thereof, at least one foam agent, at least one propellant, and with and without the addition of an active agent. The formulations may contain a solvent substantially miscible therein. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject in need thereof, comprising administering the above-mentioned compositions to an afflicted target site of said mammalian subject.

Abstract: Provided herein are methods and compositions for treating a subject who has pulmonary damage or an injury caused by or who is at risk for an injury caused by an anti-vesicant agent. The compositions comprise cacao extracts that include a mixture of epicatechin and one or more epicatechin oligomers and a pharmaceutically acceptable carrier. Also provided are methods for fermenting cacao to enhance epicatechin and antioxidant content.

Abstract: A method for styling hair comprising the steps of placing said hair in a desired configuration and applying a composition to said hair, said composition comprising (a) one or more fully soluble polymer, (b) solvent-propellant mixture or solvent mixture, and optional other ingredients. Also provided is a method of making polymer.

Abstract: The present invention provides foamable pharmaceutical compositions comprising water-soluble antibiotics and anti-inflammatory steroids and methods of preparing same. Particularly, the present invention relates to oil-free pharmaceutical compositions comprising a quinolone, an anti-inflammatory steroid, a polar co-solvent, and propellant gas, administered to the ear in the form of foam for treating ear disorders.

Abstract: Shelf stable compositions comprising olive extracts are described herein. The compositions include an olive extract comprising hydroxytyrosol, tyrosol, and oleuropein, wherein the weight ratio of hydroxytyrosol to oleuropein is 3:1 or less and the weight ratio of hydroxytyrosol to tyrosol is 2.85:1 or less. The compositions are stable for at least 12 months. Methods of using the shelf stable compositions are also described herein.

Abstract: The present invention provides pharmaceutical compositions and methods for dispensing the same using an aerosol whereby the composition takes the form of foam. Additionally, the present invention provides a barrier system including a concentrate separated from a non-chlorine aerosol propellant wherein the concentrate includes a non-aqueous solvent, an emulsifying agent, a thickening agent, at least one medicament and optionally an aqueous solvent.

Abstract: A hair fixative composition includes a hair fixative polymer and a solvent system where the solvent system includes ethanol and another non-aqueous solvent in a weight ratio in a range of about 80:20 to about 20:80 of ethanol to the other non-aqueous solvent, and optionally a propellant.

Abstract: Absorption of a therapeutic agent across a mucosal membrane or the skin can be enhanced using an absorption enhancer comprising a hydroxy fatty acid ester of polyethylene glycol.

Abstract: The present invention relates to stable substantially non-aqueous, non-alcoholic, non-silicone, foamable carrier compositions comprising petrolatum or mixtures thereof, at least one foam agent, at least one propellant, and with and without the addition of an active agent. The formulations may contain a solvent substantially miscible therein. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject in need thereof, comprising administering the above-mentioned compositions to an afflicted target site of said mammalian subject.

Abstract: The present invention generally relates to the large-scale (e.g., greater than 1 kg scale) preparation of low molecular weight polylysine or polyornithine in high yield by preparing a polylysine or polyornithine having a weight average molecular weight from about 12,500 Daltons to about 22,000 Daltons and hydrolyzing it to produce a polylysine or polyornithine having a weight average molecular weight from about 5,500 Daltons to about 12,000 Daltons.

Abstract: Provided is an arthropod pest control composition, the composition having an superior effect on control of arthropod pests. The composition comprises 0.01 to 0.5% by weight of a neonicotinoid insecticidal compound, 10 to 50% by weight of an organic solvent selected from the group consisting of monoalcohols having 1 to 3 carbon atoms and acetone, and 49.5 to 89.99% by weight of liquefied carbon dioxide, wherein the weight of ethanol to that of the neonicotinoid insecticidal compound is 100 times or more.

Abstract: Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.

Abstract: Formulations have been developed which assist individuals having an addiction such as smoking to reduce or quit engaging in the addictive behavior. Representative behaviors include smoking, excessive alcohol or food ingestion, drug addiction, and ingestion of caffeine or junk food providing quick “highs”. The formulations assist the smoker to become dissatisfied with smoking, until he or she willingly gives up the habit or at least cuts down on the number of cigarettes smoked per day as an initial step towards quitting in the future. The formulations can also be used in conjunction with other known formulations, such as nicotine gum or patch. The formulations contain hydrophilic polymers, for example, polyethylene glycol (PEG) alone or in combination or polyvinyl pyrrolidone (PVP) (also known as povidone or polyvidone alone or in combination.), sweeteners and/or flavorings, viscosity modifiers/binders, and pH or buffering agents.

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II; aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

Abstract: There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.

Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of additional pH adjusting substance in combination with the effervescent for promoting the absorption of drugs is also disclosed.

Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.

Abstract: The invention discloses a pharmaceutical hemostatic liquid foam base preparation comprising albumin as foaming agent and a fibrinogen precipitating substance and optionally a coagulation inducing agent, wherein albumin as foaming agent is present in native form; a method for the production of a transient hemostatic liquid foam; the transient hemostatic liquid foam; and a kit for making the foam.

Abstract: The present invention relates to a process for non-therapeutic treatment of human keratinous substances or mucous membranes, comprising the step consisting in transferring onto human keratinous substances or mucous membranes packets, preferably droplets (G), of a composition (P), held by capillary action or otherwise in cavities (3) in a support (2), by putting said support (2) in contact with keratinous substances or mucous membranes and/or by ejecting said packets, preferably said droplets, from the support (2) by mechanical action.

Abstract: The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.

Abstract: Described herein is a pharmaceutical composition that includes a beta2-agonist selected from indacaterol and formoterol in combination with a corticosteroid selected from fluticasone and ciclesonide, and, optionally, one or more pharmaceutically acceptable excipients.

Abstract: The present invention provides a non-parenteral and non-ocular herbal synergistic detoxifier composition effective for blood purification, blood detoxification and in the treatment and management of disorders related to accumulation of toxins in the body having synergistic effect of its components in specific ratio, better bio availability wherein the amount of dose administered is remarkably low. The formulation of synergistic herbal composition has better patient compliance in the terms of palatability, ease of administration and is formulated in the form of syrup, lozenges/candies/jujubs/mouth freshener, sub-lingual tablets or chewable tablets. The present invention also provides a method of preparation of this formulation.

Abstract: The invention relates to growth hormone (GH) formulations having sustained-release properties, in particular human growth hormone (hGH) and methods for their preparation. The growth hormone formulations can be manufactured without denaturing of the protein and can conveniently be administrated to the person in need thereof by using a conventional syringe via a needle having a small diameter.

Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.

Abstract: The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble therapeutic and cosmetic agents.

Abstract: Compositions and methods for lightening and/or depigmenting skin are provided, the compositions comprising compounds having the structure: or having the structure: as defined herein.

Abstract: The present disclosure relates to cosmetic compositions comprising an organosilane (A) having the formula: (R1)n(R2O)(3?n)SiR3O(CH2CH2O)a(C3H6O)bR4 where n is 1, 2, or 3, a?1, b may vary from 0 to 30, with the proviso a?b, R1 is a hydrocarbon group containing 1 to 12 carbon atoms, R2 is hydrogen or an alkyl group containing 1 to 6 carbon atoms, R3 is a divalent hydrocarbon group containing 2 to 12 carbon atoms, R4 is hydrogen, R1, or an acetyl group; and a cosmetic ingredient (B), and optionally in a cosmetically acceptable medium.

Abstract: Pharmaceutical or cosmetic compositions and methods for their use are provided comprising water and a surfactant polymer system comprising a Poloxamer at a concentration of about 0.1% to about 15% by weight; wherein when the Poloxamer is between about 0.1% to about 5% Poloxamer. The composition can further comprise a supporting agent comprising a non-ionic surface active agent or a supporting agent comprising a non surfactant polymer or polysaccharide and an active agent, where the Poloxamer is capable of fixing the composition on delivery to a body surface. There are further provided therapeutic cell compositions and their uses.

Abstract: A system and method for treating hoof related diseases, particularly hairy heel warts (papillomatus digital dermatitis), includes an aqueous solution having a metal astringent at a therapeutically effective concentration. The metal astringent includes aluminum, iron, and mixtures thereof. In preferred embodiments, the metal may include a mixture of monomeric and polymeric species. The polymeric species may be in the form of a polymeric concentrate, such as, for example, polyaluminum chloride or polyferric sulfate. Alternatively, the polymeric species may be formed by partially neutralizing a metal salt. The aqueous solution of the metal astringent is applied to a lower leg and hoof area of an animal using any known application technique, including, but not limited to, foot baths, foams and spray applications. In preferred embodiments, the aqueous solution is applied using an automated dispensing system.